Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics

Description

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.  Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.  This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

Author Information

By Daniel J. Lenihan, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and Douglas B. Sawyer, M.D., Ph.D., FACC , Maine Medical Center Department of Cardiac Services Portland, ME, USA